InMed Pharmaceuticals Inc
INM1.730USD
-0.120-6.49%
Cierre 11/04, 16:00（ET）Cotizaciones retrasadas 15 min
3.46MCap. mercado
PérdidaP/E TTM
Más Datos de InMed Pharmaceuticals Inc Compañía
InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Información de InMed Pharmaceuticals Inc
Símbolo de cotizaciónINM
Nombre de la empresaInMed Pharmaceuticals Inc
Fecha de salida a bolsaJun 21, 2001
Director ejecutivoMr. Eric A. Adams
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 21
Dirección1445-885 West Georgia St.
CiudadVANCOUVER
Bolsa de valoresNational Stock Exchange of India
PaísCanada
Código postalV6C 3E8
Teléfono16046697207
Sitio Webhttps://www.inmedpharma.com/
Símbolo de cotizaciónINM
Fecha de salida a bolsaJun 21, 2001
Director ejecutivoMr. Eric A. Adams
Ejecutivos de InMed Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Director
Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Director
Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 2 de oct
Actualizado: jue., 2 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Yorkville Advisors Global, LP.
3.37%
Sabby Management, LLC
1.52%
UBS Financial Services, Inc.
0.33%
Adams (Eric Ashley)
0.09%
Hull (Andrew Harold)
0.08%
Otro
94.62%
Accionistas
Accionistas
Proporción
Yorkville Advisors Global, LP.
3.37%
Sabby Management, LLC
1.52%
UBS Financial Services, Inc.
0.33%
Adams (Eric Ashley)
0.09%
Hull (Andrew Harold)
0.08%
Otro
94.62%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
4.89%
Investment Advisor
0.33%
Individual Investor
0.17%
Hedge Fund
0.02%
Research Firm
0.01%
Otro
94.59%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
29
124.98K
5.24%
+38.52K
2025Q2
37
127.03K
6.34%
+18.71K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Yorkville Advisors Global, LP.
80.37K
3.37%
+80.37K
--
Dec 13, 2024
Sabby Management, LLC
36.13K
1.52%
+20.77K
+135.22%
Dec 31, 2024
UBS Financial Services, Inc.
7.76K
0.33%
+1.66K
+27.12%
Jun 30, 2025
Adams (Eric Ashley)
2.20K
0.09%
-5.70K
-72.17%
Jun 30, 2025
Hull (Andrew Harold)
1.91K
0.08%
-425.00
-18.19%
Jun 30, 2025
Tower Research Capital LLC
400.00
0.02%
+400.00
--
Jun 30, 2025
SBI Securities Co., Ltd.
300.00
0.01%
--
--
Jun 30, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Jun 30, 2025
Hsu (Eric Chih-Hsien)
2.00
0%
-1.95K
-99.90%
Jun 30, 2025
Bessemer Trust Company, N.A. (US)
1.00
0%
+1.00
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Fecha
Tipo
Relación
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
